Oyster Point Pharma Long Term Debt

Oyster Point Pharma (OYST) currently reports a long-term debt of $94M as of September 2022. That compares with $42M in the prior-year period — up 123.4% year over year. Use the charts on this page to explore Oyster Point Pharma's long-term debt history and peer comparisons.

Oyster Point Pharma's long-term debt increased from $42M to $94M — a 123.4% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Oyster Point Pharma reported $94M in long-term debt as of September 2022. That compares with $42M in the prior-year period — up 123.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $94M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Oyster Point Pharma, and consider following OYST for alerts when major investors trade the stock.

Oyster Point Pharma is classified in the Healthcare sector. On long-term debt, it currently shows $94M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OYST with unrelated industries.